{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T17:20:31Z","timestamp":1787678431036,"version":"build-2784847793"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bioorg.2026.110207","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T06:45:44Z","timestamp":1783061144000},"page":"110207","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Preparation, in vitro evaluation, and biodistribution study of a novel PSMA-targeted radioligand"],"prefix":"10.1016","volume":"180","author":[{"given":"Xiao","family":"Ji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangsheng","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenchen","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongzhang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sihui","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.110207_bb0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bioorg.2026.110207_bb0010","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The lancet commission on prostate cancer: planning for the surge in cases","volume":"403","author":"James","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.bioorg.2026.110207_bb0015","first-page":"8","article-title":"Cancer statistics 2024: all hands on deck","volume":"74","author":"Dizon","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bioorg.2026.110207_bb0020","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13143556","article-title":"Evolving castration resistance and prostate specific membrane antigen expression: implications for patient management","volume":"13","author":"Kessel","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.bioorg.2026.110207_bb0025","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41585-024-00900-z","article-title":"Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer","volume":"22","author":"Bakht","year":"2025","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.bioorg.2026.110207_bb0030","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(24)00326-7","article-title":"Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study","volume":"25","author":"Karpinski","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bioorg.2026.110207_bb0035","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16173039","article-title":"From oncogenesis to theranostics: the transformative role of PSMA in prostate cancer","volume":"16","author":"Hameed","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.bioorg.2026.110207_bb0040","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.neuroscience.2006.10.022","article-title":"Expression of glutamate carboxypeptidase II in human brain","volume":"144","author":"\u0160\u00e1cha","year":"2007","journal-title":"Neuroscience"},{"key":"10.1016\/j.bioorg.2026.110207_bb0045","doi-asserted-by":"crossref","first-page":"551","DOI":"10.4161\/cbt.3.6.846","article-title":"Use of methotrexate-based peptide substrates to characterize the substrate specificity of prostate-specific membrane antigen (PSMA)","volume":"3","author":"Mhaka","year":"2004","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.bioorg.2026.110207_bb0050","first-page":"3192","article-title":"Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature","volume":"59","author":"Chang","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110207_bb0055","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1046\/j.0022-3042.2001.00715.x","article-title":"Substrate specificity, inhibition and enzymological analysis of recombinant human glutamate carboxypeptidase II","volume":"80","author":"Barinka","year":"2002","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bioorg.2026.110207_bb0060","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.2174\/092986712799462667","article-title":"Glutamate carboxypeptidase II: an overview of structural studies and their importance for structure-based drug design and deciphering the reaction mechanism of the enzyme","volume":"19","author":"Pavl\u00edcek","year":"2012","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110207_bb0065","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1093\/nar\/30.1.343","article-title":"MEROPS: the protease database","volume":"30","author":"Rawlings","year":"2002","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bioorg.2026.110207_bb0070","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.jmb.2007.12.066","article-title":"Structural basis of interactions between human glutamate carboxypeptidase II and its substrate analogs","volume":"376","author":"Barinka","year":"2008","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.bioorg.2026.110207_bb0075","doi-asserted-by":"crossref","first-page":"12296","DOI":"10.1021\/acs.jmedchem.4c02626","article-title":"Prodrugs targeting prostate-specific membrane antigen against prostate cancer","volume":"68","author":"Liolios","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110207_bb0080","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1021\/acs.bioconjchem.4c00297","article-title":"A unique prodrug targeting the prostate-specific membrane antigen for the delivery of monomethyl auristatin E","volume":"36","author":"Bomba","year":"2025","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.bioorg.2026.110207_bb0085","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1007\/s00259-024-07044-7","article-title":"JHU-2545 preferentially shields salivary glands and kidneys during PSMA-targeted imaging","volume":"52","author":"Nedelcovych","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.bioorg.2026.110207_bb0090","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijrobp.2021.03.055","article-title":"FDA approves Ga 68 PSMA-11 for prostate cancer imaging","volume":"111","author":"Masters","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.bioorg.2026.110207_bb0095","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1158\/1078-0432.CCR-22-2875","article-title":"FDA approval summary: lutetium Lu 177 Vipivotide Tetraxetan for patients with metastatic castration-resistant prostate cancer","volume":"29","author":"Fallah","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110207_bb0100","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27103062","article-title":"The chemical scaffold of theranostic radiopharmaceuticals: radionuclide, bifunctional chelator, and pharmacokinetics modifying linker","volume":"27","author":"Holik","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2026.110207_bb0105","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s00259-015-3188-1","article-title":"68Ga-PSMA-11 PET\/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients","volume":"43","author":"Sterzing","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.bioorg.2026.110207_bb0110","doi-asserted-by":"crossref","first-page":"914","DOI":"10.2967\/jnumed.114.147413","article-title":"Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer","volume":"56","author":"Bene\u0161ov\u00e1","year":"2015","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bioorg.2026.110207_bb0115","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2967\/jnumed.123.265986","article-title":"Long-term nephrotoxicity of 177Lu-PSMA radioligand therapy","volume":"65","author":"Steinhelfer","year":"2024","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bioorg.2026.110207_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101295","article-title":"Nephrotoxicity after radionuclide therapies","volume":"15","author":"Parihar","year":"2022","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.bioorg.2026.110207_bb0125","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1483953","article-title":"Initial clinical experience with [177Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial","volume":"14","author":"Hansen","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bioorg.2026.110207_bb0130","doi-asserted-by":"crossref","first-page":"268","DOI":"10.2174\/0929867328666210804092200","article-title":"The importance of linkers in the structure of PSMA ligands","volume":"29","author":"Uspenskaya","year":"2022","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110207_bb0135","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.7150\/thno.118972","article-title":"Optimizing PSMA-617-based inhibitors through charged linker modifications: insights into structure-activity relationships","volume":"16","author":"Geis","year":"2026","journal-title":"Theranostics"},{"key":"10.1016\/j.bioorg.2026.110207_bb0140","doi-asserted-by":"crossref","first-page":"7077","DOI":"10.1021\/acsomega.4c10142","article-title":"Structure-activity relationships and biological insights into PSMA-617 and its derivatives with modified lipophilic linker regions","volume":"10","author":"Sch\u00e4fer","year":"2025","journal-title":"ACS Omega"},{"key":"10.1016\/j.bioorg.2026.110207_bb0145","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1021\/acsptsci.4c00257","article-title":"Effect of linker entities on pharmacokinetics of 111In-labeled prostate-specific membrane antigen-targeting ligands with an albumin binder","volume":"7","author":"Kazuta","year":"2024","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.bioorg.2026.110207_bb0150","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1007\/s00259-024-06726-6","article-title":"Development and first-in-human study of PSMA-targeted PET tracers with improved pharmacokinetic properties","volume":"51","author":"Hou","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.bioorg.2026.110207_bb0155","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s41181-025-00389-w","article-title":"Paving the way for future PSMA inhibitors: insights from comparative preclinical evaluations of structure modifications","volume":"10","author":"Hajduov\u00e1","year":"2025","journal-title":"EJNMMI Radiopharm. Chem."},{"key":"10.1016\/j.bioorg.2026.110207_bb0160","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1021\/acs.jcim.1c00203","article-title":"AutoDock Vina 1.2.0: new docking methods, expanded force field, and python bindings","volume":"61","author":"Eberhardt","year":"2021","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.bioorg.2026.110207_bb0165","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.bioorg.2026.110207_bb0170","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.bioorg.2026.110207_bb0175","series-title":"The PyMOL Molecular Graphics System, Version 2.6 [Software]","author":"Schr\u00f6dinger, LLC","year":"2023"},{"key":"10.1016\/j.bioorg.2026.110207_bb0180","series-title":"Discovery Studio Visualizer, Version 2024 [Software]","author":"Dassault Syst\u00e8mes BIOVIA","year":"2024"},{"key":"10.1016\/j.bioorg.2026.110207_bb0185","series-title":"X-ray structure of human glutamate carboxypeptidase II (GCPII) in complex with a urea based inhibitor PSMA 1007,","author":"Barinka","year":"2017"},{"key":"10.1016\/j.bioorg.2026.110207_bb0190","doi-asserted-by":"crossref","first-page":"D1516","DOI":"10.1093\/nar\/gkae1059","article-title":"PubChem 2025 update","volume":"53","author":"Kim","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bioorg.2026.110207_bb0195","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.2967\/jnumed.122.264225","article-title":"MIRD Pamphlet No. 28, Part 1: MIRDcalc-A Software Tool for Medical Internal Radiation Dosimetry","volume":"64","author":"Kesner","year":"2023","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bioorg.2026.110207_bb0200","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.2967\/jnumed.124.268011","article-title":"MIRD Pamphlet No. 30: MIRDfit-A Tool for Fitting of Biodistribution Time-Activity Data for Internal Dosimetry","volume":"65","author":"Carter","year":"2024","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bioorg.2026.110207_bb0205","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s00259-021-05446-5","article-title":"Impact of the mouse model and molar amount of injected ligand on the tissue distribution profile of PSMA radioligands","volume":"49","author":"Tschan","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.bioorg.2026.110207_bb0210","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.2967\/jnumed.125.269744","article-title":"[(225) Ac]Ac-PSMA I&T: a preclinical investigation on the fate of decay nuclides and their influence on dosimetry of salivary glands and kidneys","volume":"66","author":"Wurzer","year":"2025","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bioorg.2026.110207_bb0215","doi-asserted-by":"crossref","first-page":"5460","DOI":"10.1038\/s41467-021-25746-6","article-title":"A prostate-specific membrane antigen activated molecular rotor for real-time fluorescence imaging","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2026.110207_bb0220","doi-asserted-by":"crossref","first-page":"32658","DOI":"10.1039\/C4RA02458C","article-title":"Solid-phase peptide synthesis: an overview focused on the preparation of biologically relevant peptides","volume":"4","author":"Palomo","year":"2014","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2026.110207_bb0225","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/pros.22789","article-title":"Improving the biodistribution of PSMA-targeting tracers with a highly negatively charged linker","volume":"74","author":"Huang","year":"2014","journal-title":"Prostate"},{"key":"10.1016\/j.bioorg.2026.110207_bb0230","doi-asserted-by":"crossref","first-page":"7737","DOI":"10.1021\/jm800765e","article-title":"Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterization","volume":"51","author":"Barinka","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110207_bb0235","doi-asserted-by":"crossref","first-page":"12711","DOI":"10.1021\/ja104591m","article-title":"A remote arene-binding site on prostate specific membrane antigen revealed by antibody-recruiting small molecules","volume":"132","author":"Zhang","year":"2010","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bioorg.2026.110207_bb0240","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1038\/sj.emboj.7600969","article-title":"Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer","volume":"25","author":"Mesters","year":"2006","journal-title":"EMBO J."},{"key":"10.1016\/j.bioorg.2026.110207_bb0245","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.toxlet.2019.01.009","article-title":"Naphthalene genotoxicity: DNA adducts in primate and mouse airway explants","volume":"305","author":"Carratt","year":"2019","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.bioorg.2026.110207_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.128044","article-title":"Dipeptide inhibitors of the prostate specific membrane antigen (PSMA): a comparison of urea and thiourea derivatives","volume":"42","author":"Young","year":"2021","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110207_bb0255","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13550-018-0440-2","article-title":"Synthesis and in vitro and in vivo evaluation of urea-based PSMA inhibitors with increased lipophilicity","volume":"8","author":"Wirtz","year":"2018","journal-title":"EJNMMI Res."},{"key":"10.1016\/j.bioorg.2026.110207_bb0260","first-page":"1005","article-title":"Demonstrating the absence of correlation between molecular docking and in vitro cytotoxicity in anti-breast cancer research: root causes and practical resolutions","volume":"17","author":"Megantara","year":"2025","journal-title":"Breast Cancer"},{"key":"10.1016\/j.bioorg.2026.110207_bb0265","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1021\/acs.accounts.4c00093","article-title":"Advancing ligand docking through deep learning: challenges and prospects in virtual screening","volume":"57","author":"Zhang","year":"2024","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.bioorg.2026.110207_bb0270","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19103251","article-title":"PSMA-oriented target delivery of novel anticancer prodrugs: design, synthesis, and biological evaluations of oligopeptide-camptothecin conjugates","volume":"19","author":"Xu","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.110207_bb0275","doi-asserted-by":"crossref","first-page":"4000","DOI":"10.1007\/s00259-022-05884-9","article-title":"PET imaging of hepatocellular carcinoma by targeting tumor-associated endothelium using [(68)Ga]Ga-PSMA-617","volume":"49","author":"Lu","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.bioorg.2026.110207_bb0280","series-title":"Bioanalytical method validation guidance for industry","author":"U.S. Department of Health and Human Services, Food and Drug Administration","year":"2018"},{"key":"10.1016\/j.bioorg.2026.110207_bb0285","doi-asserted-by":"crossref","first-page":"10812","DOI":"10.1021\/acs.analchem.3c02163","article-title":"LC-MS\/MS bioanalysis of radioligand therapeutic drug candidate for preclinical toxicokinetic assessment","volume":"95","author":"Fu","year":"2023","journal-title":"Anal. Chem."},{"key":"10.1016\/j.bioorg.2026.110207_bb0290","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16030299","article-title":"Liquid chromatography ICP-MS to assess the stability of (175) Lu-and (nat) Ga-based tumor-targeting agents towards the development of (177) Lu-and (68) Ga-labeled radiopharmaceuticals","volume":"16","author":"Wallimann","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bioorg.2026.110207_bb0295","doi-asserted-by":"crossref","first-page":"11868","DOI":"10.1038\/s41598-025-96764-3","article-title":"Development and validation of an LC-MS\/MS method for quantitative determination of LXT-101 sustained-release suspension, a novel drug in treating prostate cancer, in beagle plasma","volume":"15","author":"Li","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2026.110207_bb0300","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jala.2010.06.002","article-title":"Development and validation of a higher-throughput equilibrium dialysis assay for plasma protein binding","volume":"16","author":"van Liempd","year":"2011","journal-title":"J. Lab. Autom."},{"key":"10.1016\/j.bioorg.2026.110207_bb0305","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/j.bbamem.2012.03.001","article-title":"Binding of cationic pentapeptides with modified side chain lengths to negatively charged lipid membranes: complex interplay of electrostatic and hydrophobic interactions","volume":"1818","author":"Hoernke","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bioorg.2026.110207_bb0310","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1093\/nar\/2.10.1839","article-title":"The estimation of affinity constants for the binding of model peptides to DNA by equilibrium dialysis","volume":"2","author":"Standke","year":"1975","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bioorg.2026.110207_bb0315","first-page":"406","article-title":"Thermodynamics of dialysis equilibrium & excess hydration of proteins: part 2--negative binding of inorganic electrolytes & lyotropic series","volume":"16","author":"Chattoraj","year":"1979","journal-title":"Indian J. Biochem. Biophys."},{"key":"10.1016\/j.bioorg.2026.110207_bb0320","unstructured":"GraphPad Software. How does prism compute \"area under the curve\" (AUC)? What are its units? GraphPad Prism User Guide Available online: https:\/\/www.graphpad.com\/support\/faq\/how-does-prism-compute-area-under-the-curve-auc-what-are-its-units\/ (accessed 18 June 2026)."},{"key":"10.1016\/j.bioorg.2026.110207_bb0325","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2967\/jnumed.122.264225","article-title":"MIRD pamphlet No. 28, Part 1: MIRDcalc\u2014a software tool for medical internal radiation dosimetry","volume":"64","author":"Kesner","year":"2023","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bioorg.2026.110207_bb0330","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.2967\/jnumed.119.233411","article-title":"Radiation dosimetry in (177) Lu-PSMA-617 therapy using a single posttreatment SPECT\/CT scan: a novel methodology to generate time- and tissue-specific dose factors","volume":"61","author":"Jackson","year":"2020","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bioorg.2026.110207_bb0335","article-title":"Integration of multiple time point imaging in clinical dosimetry: practical considerations","volume":"66","author":"Akerele","year":"2025","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bioorg.2026.110207_bb0340","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40658-023-00529-8","article-title":"Investigation of image-based lesion and kidney dosimetry protocols for 177Lu-PSMA-I&T therapy with and without a late SPECT\/CT acquisition","volume":"10","author":"Resch","year":"2023","journal-title":"EJNMMI Phys."},{"key":"10.1016\/j.bioorg.2026.110207_bb0345","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1007\/s12149-024-01957-x","article-title":"Physiological biodistribution on Ga68-PSMA PET\/CT and the factors effecting biodistribution","volume":"38","author":"Ar\u00e7ay \u00d6zt\u00fcrk","year":"2024","journal-title":"Ann. Nucl. Med."},{"key":"10.1016\/j.bioorg.2026.110207_bb0350","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S1470-2045(25)00009-9","article-title":"Overall survival and quality of life with [177Lu] Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial","volume":"26","author":"Emmett","year":"2025","journal-title":"Lancet Oncol."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826007431?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826007431?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T16:29:41Z","timestamp":1787675381000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826007431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":70,"alternative-id":["S0045206826007431"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110207","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preparation, in vitro evaluation, and biodistribution study of a novel PSMA-targeted radioligand","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110207","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110207"}}